Timothy Coughlin
Sits on 5 boards. Overboarded · 5 public boards Last updated September 28, 2026
Time on boards
- Boards served
- 5
- Current seats
- 5
- Board service
- 12 years
- Director since
- 2023
12 years of board service in total across 5 boards, counting each seat separately. Longest: aTyr Pharma Inc., 3 years.
Shareholder support
Support is votes for as a share of votes for and against (or withheld). Below 80% is a clear protest.
-
ADC Therapeutics SA June 1, 202699.5%
-
Travere Therapeutics Inc. May 19, 202697.2%
-
ADC Therapeutics SA June 3, 202599.7%
-
Travere Therapeutics Inc. May 15, 202598.7%
-
Travere Therapeutics Inc. May 8, 202496.1%
-
aTyr Pharma Inc. May 17, 202391.0%
-
Travere Therapeutics Inc. May 17, 202395.0%
Insider trades
All notable trades →From SEC Forms 4 and 5. Open-market purchases and sales are highlighted; grants, option exercises and shares withheld for tax are routine.
| Date | Company | Transaction | Shares | Price | Value |
|---|---|---|---|---|---|
| Jun 12, 2026 | Travere Therapeutics Inc. | Option exercise | +10,000 | $26.52 | $265,200 |
| Jun 12, 2026 | Travere Therapeutics Inc. | Open-market sale | −10,000 | $50.07 | $500,700 |
| Jun 9, 2026 | Vir Biotechnology Inc. | Grant or award | +8,000 | — | — |
| Jun 9, 2026 | Vir Biotechnology Inc. | Grant or award | +8,000 | — | — |
| Jun 3, 2026 | ADC Therapeutics SA | Shares withheld for tax | −12,600 | $3.08 | $38,808 |
| Jun 1, 2026 | ADC Therapeutics SA | Grant or award | +45,000 | — | — |
| May 19, 2026 | Travere Therapeutics Inc. | Grant or award | +4,000 | — | — |
| May 15, 2026 | Travere Therapeutics Inc. | Open-market sale | −3,250 | $43.49 | $141,343 |
| Oct 31, 2025 | Travere Therapeutics Inc. | Option exercise | +8,000 | $16.33 | $130,640 |
| Oct 31, 2025 | Travere Therapeutics Inc. | Option exercise | +10,000 | $17.44 | $174,400 |
| Oct 31, 2025 | Travere Therapeutics Inc. | Open-market sale | −18,000 | $35.03 | $630,540 |
| Jun 3, 2025 | ADC Therapeutics SA | Grant or award | +40,000 | — | — |
| May 15, 2025 | Travere Therapeutics Inc. | Grant or award | +6,500 | — | — |
| May 30, 2024 | aTyr Pharma Inc. | Open-market purchase | +50,000 | $1.75 | $87,500 |
| May 8, 2024 | Travere Therapeutics Inc. | Grant or award | +6,500 | — | — |
Questions about Timothy Coughlin
What boards is Timothy Coughlin on?
Timothy Coughlin sits on the boards of ADC Therapeutics SA, Fate Therapeutics Inc., Travere Therapeutics Inc., Vir Biotechnology Inc. and aTyr Pharma Inc.
How long has Timothy Coughlin served on boards?
Our records show at least 12 years of board service across 5 boards, the earliest from 2023.
Reviews (0)
Sign in to write a review.
No reviews yet. Be the first to write one.